Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo gets go-ahead for new infant products

This article was originally published in The Tan Sheet

Executive Summary

FDA approves Perrigo's first new infant formula products since the Allegan, Mich., firm acquired PBM Holdings in March. Perrigo's partner, Quebec-based Kerry Proteins and Nutritionals, will manufacture the products, the private labeler said Aug. 23. The approved products include concentrate and ready-to-use milk-based infant formula with arachidonic and docosahexaenoic acids. The ready-to-use product also comes in an organic version. "This is the first launch of new products since acquiring our infant nutrition business and we look forward to further new product introductions," said CEO Joseph Papa. Collins Stewart analysts said the approvals allow Perrigo to produce store brands to compete with Abbott's Similac Advance and Mead Johnson's Enfamil Premium (1"The Tan Sheet" March 29, 2010)

You may also be interested in...



Perrigo Grows Into Adjacent Infant Formula Category With PBM Acquisition

Perrigo takes the next step toward becoming a one-stop shop for private-label consumer health products with its $808 million acquisition of infant formula and baby food firm PBM Holdings Inc

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Topics

UsernamePublicRestriction

Register

PS104454

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel